公司概覽
業務類別 Diagnostics & Research
業務概覽 Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
公司地址 5200 Illumina Way, San Diego, CA, USA, 92122
電話號碼 +1 858 202-4500
傳真號碼 +1 858 202-4545
公司網頁 https://www.illumina.com
員工數量 10080
 
公司高管 / 董事會成員
公司高管
高管 職務 年薪 更新日期
Ms. Patricia Leckman Chief People Officer -- 09/04/2025
Mr. Scott M. Davies Chief Legal Officer and Secretary -- 23/05/2025
Mr. Ankur Dhingra Chief Financial Officer 美元 450.00K 12/02/2026
Mr. Scott Ericksen Vice President and Chief Accounting Officer -- 12/02/2026
Dr. Steve Barnard, PhD Chief Technology Officer 美元 593.27K 09/04/2025
Mr. Christensen Jakob Wedel Chief Strategy and Corporate Development Officer -- 09/04/2025
Mr. Jacob Thaysen Director and Chief Executive Officer 美元 1.00M 12/02/2026
Mr. Kevin Carl Pegels Chief of Global Operations 美元 561.54K 09/04/2025
 
董事會成員
董事會 職務 更新日期
Ms. Caroline D. Dorsa Independent Director 12/02/2026
Ms. Anna S. Richo Independent Director 12/02/2026
Dr. Gary S. Guthart,PhD Independent Director 12/02/2026
Mr. Philip W. Schiller Independent Director 12/02/2026
Ms. Susan E. Siegel Independent Director 12/02/2026
Dr. Robert S. Epstein, M.D.,M.S. Independent Director 12/02/2026
Dr. Scott Gottlieb,M.D. Chairman of the board 12/02/2026
Dr. Frances H. Arnold, PhD Independent Director 12/02/2026
Mr. Scott B. Ullem Independent Director 12/02/2026
Mr. Keith A. Meister Director 12/02/2026
Mr. Jacob Thaysen Director and Chief Executive Officer 12/02/2026
 
所屬ETF (更新日期: 07/03/2026 03:20)
代號 名稱 佔比% 持有日期
IJHiShares Core S&P Mid-Cap ETF3.23%28/02/2026
XMHQInvesco S&P MidCap Quality ETF0.97%27/02/2026
IBBiShares Biotechnology ETF0.73%28/02/2026
MDYState Street® SPDR® S&P MIDCAP 400® ETF0.72%31/01/2026
EMMState Street SPDR Port S&P 400 Md CpETF0.48%27/02/2026
ARKKARK Innovation ETF0.45%26/02/2026
FBTFirst Trust NYSE Arca Biotech ETF0.38%26/02/2026
IWRiShares Russell Mid-Cap ETF0.37%28/02/2026
VHTVanguard Health Care ETF0.30%31/01/2026
ARKGARK Genomic Revolution ETF0.26%26/02/2026
IJJiShares S&P Mid-Cap 400 Value ETF0.23%28/02/2026
IWDiShares Russell 1000 Value ETF0.22%28/02/2026
CGGRCapital Group Growth ETF0.21%31/01/2026
FMDEFidelity Enhanced Mid Cap ETF0.17%27/02/2026
IVOOVanguard S&P Mid-Cap 400 ETF0.15%31/01/2026
ITOTiShares Core S&P Total US Stock Mkt ETF0.12%28/02/2026
ROBORobo Global® Robotics&Automation ETF0.12%27/02/2026
CGBLCapital Group Core Balanced ETF0.10%31/01/2026
SCHXSchwab US Large-Cap ETF™0.10%28/02/2026
BAFEBrown Advisory Flexible Equity ETF0.09%27/02/2026
 1    2    3  
 

Copyright © 2026 ET Net Limited.
All rights reserved. Use of this site signifies your agreement to the terms of use.
DISCLAIMER: ET Net Limited and Third Party Information Providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.